Platforms
Our platform power
ACCELERATING DISCOVERY & UNLOCKING INNOVATIVE THERAPIES
YUMAB advanced platforms to precisely target diseased cells are the foundation of our contract research services. Whether accessing challenging intracellular molecules or harnessing immune cells for powerful responses, our technologies provide high specificity, safety, and flexibility. Designed for efficiency and reliability, they enable rapid exploration of new therapeutic approaches.
TCRm ANTIBODY DISCOVERY PLATFORM ENSURES PRECISION
TCR-mimic (TCRm) antibodies open a new dimension in targeted therapy by combining the unique specificity of T-cell receptors (TCR) with the robustness of antibodies. Unlike traditional antibodies that recognize cell-surface proteins, TCRm antibodies bind to peptide–HLA (pHLA) complexes and therefore access the new and vast landscape of intracellular antigens. This enables highly selective targeting of diseased cells while preserving healthy tissue.
At YUMAB, we know specificity is everything and is one of the major challenges in TCRm design. To face that challenge we developed a cutting-edge CHO display library that represents the natural human peptide:HLA (pHLA) repertoire, helping us filter out non-specific TCRm candidates from the start. Our discovery workflow addresses all clinically relevant features – specificity, safety, precision and stability and provides TCRm antibodies useful in T cell engager formats.
YUMAB’s Versatile
TCE Platform
YUMAB has developed a proprietary humanized CD3 VHH antibody that serves as a versatile building block for T-cell engagers in bispecific formats. Their small size, high stability and precision binding make it ideal for recruiting T cells to target diseased cells effectively. Designed for flexibility, it can be incorporated into a wide range of therapeutic antibody formats, maximizing potential clinical applications. With this innovative CD3 VHH, YUMAB empowers the creation of next-generation immunotherapies that combine potency, specificity, and safety.
YUMAB’s Transferrin Receptor Antibody for Targeted Brain Delivery
YUMAB’s transferrin receptor-specific antibody serves as a versatile transporter for delivering therapeutic cargo across the blood–brain barrier. By harnessing the natural receptor-mediated transport pathway, it enables efficient and selective delivery of drugs, biologics, or other payloads to the brain while minimizing off-target effects. Its high specificity, stability, and modular design make it ideal for incorporation into a wide range of therapeutic constructs, from small molecules to complex biologics. This platform empowers the development of next-generation CNS therapies, expanding treatment possibilities for neurological diseases that were previously difficult to address